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Corporate practices and the health of populations: a research 
and translational agenda
Recognition is growing of the influence of corporate 
activity on the health of populations.1 Disciplines such 
as epidemiology,2 anthropology,3 ethics,4 and law5 are 
beginning to inform frameworks to study corporate 
power and influence.6 This developing field of study has 
embraced a range of methods, some of which are new 
to public health, such as network7 and textual analyses,8 
and some of which are more established approaches, 
such as modelling and policy impact assessments.9 
Encouragingly, research funders have begun to show 
interest in the effects of corporate practices on health. 
As the study of commercial determinants of health 
continues to expand, we highlight four conceptual and 
methodological challenges that hinder its development, 
and suggest productive areas for future research.
First, conceptually, what is meant by commercial 
determinants of health is still unclear. Sometimes they 
are understood as harmful products that have direct 
effects on health, such as tobacco. At other times, 
these determinants include a much broader range of 
activities that promote the interests of corporations at 
the expense of the public, such as lobbying to reduce 
corporate taxation, erode labour rights, or dilute 
or delay measures that protect health at national, 
regional, and global levels. Corporations of substantial 
size and scope influence population health in myriad 
intersectional ways, across national borders. An 
agreement is therefore needed on a common, inclusive 
definition of the commercial determinants of health, 
within which different frameworks might sit. This 
agreement will require theoretical work that draws on 
multiple disciplines. Recent work building on insights 
from ethics4 or political science that are focused on the 
nature and distribution of power6 points to a possible 
way forward.
Second, much existing research happens in discrete, 
industry-specific silos, with researchers working in 
isolation to study particular product categories, such 
as tobacco, alcohol, or gambling. Notable exceptions 
exist, with some researchers studying corporations as 
entities operating in many different sectors.10 However, 
much more could be done to develop an understanding 
of how different corporations use the same methods. 
By working across sectors, researchers could develop 
new frameworks in which to situate existing research, 
effectively identify knowledge gaps, and aid in the 
development of solutions. These activities will be crucial 
to address the cumulative effects of corporate activity 
on areas such as social norms and public discourse.
Third, much of the work on methodologies to study 
corporate practices and health has focused on analysis 
of documentary sources, such as internal documents, 
evidence submissions during policy development, 
stakeholder interviews, annual reports, or court filings. 
Little quantitative research has been done on the 
effects of different strategies, products, and networks 
of influence. This absence of empirical research is 
problematic in several ways. Without quantitative 
analysis based on sound theoretical frameworks and 
appropriate conceptual models, it is difficult to draw 
inference about the magnitude of the distal effects of 
individual or collective corporate actions on the health of 
populations, be they positive or negative. More research 
on corporate action and health that is grounded in the 
science of population health is therefore needed, using 
data sources such as social media that can illuminate 
associations between corporate actions and public 
conversations or health behaviours.
Last, the focus of much of the existing research has 
been in high-income countries, which is problematic for 
two reasons. First, corporate practices are, by definition, 
embedded in political economies that are country—or 
at least regionally—specific, suggesting that lessons 
learnt from high-income countries might have limited 
tractability in other national contexts. Also, at a global 
level, many of the corporations affecting health are 
based in high-income countries, whereas their effects 
are seen in low-income and middle-income settings, 
something that is likely to increase as markets for some 
harmful products stagnate in high-income countries.
Given these challenges, we propose three potential 
approaches that could advance the study of the 
commercial determinants of health. First, cross-
disciplinary work is the highest priority. Beyond empirical 
research, such work will require the creation of research 
architecture (including journals and academic societies) 
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that compiles what we know about commercial deter-
minants. These can in turn provide the frameworks for 
building research capacity at a global level.
Second, more purposeful and forward-looking research 
funding is needed. Commercial determinants of health 
have not been on the agenda of many funders, despite 
the clear importance for population health, both 
nationally and globally. This shortage of resources has 
led to a scarcity of scholars and networks to support 
them. Funding is needed for research that is not limited 
to individual empirical studies, but seeks to advance 
conceptual understanding of the effects of commercial 
determinants of health.
Last, what evidence does exist often has little influence 
on policy choices. The evidence base points to a need to 
take account of the actions of corporations that affect 
health in many areas of policy. With this in mind, it 
is imperative that researchers participate in broader 
conversations with the public, policy makers, and the 
media about how existing evidence might better inform 
areas such as regulation, public–private partnerships, 
and trade.
As the world grapples with challenges such as obesity, 
climate change, and environmental damage, it is be-
coming more important than ever that research helps 
redefine what responsible, sustainable corporate practice 
might look like in a future healthy society. 
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